
    
      The objective of this phase IIb study is to assess the preliminary effects on the oxygenation
      parameters of an antisense oligonucleotide that inhibits pre-kallikrein synthesis in patients
      with moderate to severe COVID-19.

      This is a blind randomized pilot clinical study which aims to include 110 patients (55 per
      arm).
    
  